Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Mark Fleury, PhD

Advertisement

Articles by Mark Fleury, PhD

Mark Fleury, PhD

Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

ByMark Fleury, PhD
April 29th 2021

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

    2

    TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

    3

    Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

    4

    SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer

    5

    Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us